This announcement is a separate document:
上海市方达律师事务所关于诺诚健华医药有限公司（InnoCare Pharma Limited）2023年科创板限制性股票激励计划预留授予相关事项的法律意见书
Legal Opinion of Shanghai Fangda Law Firm on matters relating to the reservation grant of InnoCare Pharma Limited (InnoCare Pharma Limited)'s 2023 Science and Technology Innovation Board Restricted Stock Incentive Plan
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.